Nexalin secures U.S. patent through 2042 for anxiety, depression, insomnia
NXL•Nexalin Technology has received U.S. Patent No. 12,629,519 covering transcranial alternating current dynamic frequency stimulation for anxiety, depression and insomnia, securing IP protection through 2042. The patent strengthens its DIFS™ platform and supports HALO™ Clarity and Nexalin NeuroCare™ virtual clinic strategies targeting large neuropsychiatric markets.
1. Patent Issuance and Scope
U.S. Patent No. 12,629,519 grants Nexalin exclusive rights through 2042 for transcranial alternating current dynamic frequency stimulation methods specifically designed to treat anxiety, depression and insomnia.
2. Strengthening IP Portfolio
The patent expands Nexalin’s intellectual property portfolio, reinforcing its leadership in non-invasive, frequency-based deep-brain neurostimulation and enhancing long-term defensibility for its core DIFS™ technology.
3. Platform and Market Impact
This IP protection underpins the HALO™ Clarity device and the Nexalin NeuroCare™ virtual clinic model, positioning the company to address large underserved mental health markets and advance clinical development and commercialization.
